NCT07569250 Increasing CRC Screening in Community Health Centers Through Mobile Messaging Optimization
| NCT ID | NCT07569250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Colorectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 7,220 participants |
| Start Date | 2026-12 |
| Primary Completion | 2031-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 7,220 participants in total. It began in 2026-12 with a primary completion date of 2031-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this interventional study is to create and test a comprehensive and low burden text message program within existing Community Health Centers (CHC) electronic records system to encourage patients to complete at home colorectal cancer (CRC) screening and to make sure they get follow-up care if their results are abnormal. First, the investigators will learn from clinic staff and patients what their needs and preferences are in terms of use of technology. This information will be used to design the text messages program. * Clinic patients will participate in focus groups * Clinic staff will participate in interviews Second, the investigators will test a series of different message versions in two batches (experiments): * Clinic patients with orders for an at-home colorectal cancer screening kit will receive the different message versions. * In the first batch, the messages that get the most engagement from patients will be selected to be used in the second experiment. * In the second batch, the investigators will test which messages lead to the most colorectal cancer screening completion. * This will be rolled-out within the clinics existing electronic record system. The study team will not receive any information that will identify individual patients. Lastly, the investigators will check again with clinic staff to learn how the program performed, and what would be needed to continue using the text message program in the long run. -Clinic staff will participate in interviews and surveys.
Eligibility Criteria
Eligibility Criteria for CHC Patients Cohorts Inclusion Criteria (CHC Patients): * Adults 45-75 years old * Receive care in partner CHCs * Are of average risk for colorectal cancer * Received a stool-based testing order at their CHC * Have a mobile phone and can receive text messages (Aim 1 quantitative cohort only) * Fluent in English, Spanish, or another predominant language to be identified by the PI (applicable to patients focus groups cohort only) Exclusion Criteria (CHC Patients): * Personal or family history of CRC or colorectal polyps * History of inflammatory bowel disease * Heritable conditions that put them at above average risk for colorectal cancer (e.g., familial adenomatous polyposis) Eligibility Criteria for CHC Staff Cohorts Inclusion Criteria (CHC Staff) * Adult employees of participating CHCs * Job responsibilities include activities related to CRC screening Exclusion Criteria (CHC Staff) * None
Contact & Investigator
Gina Kruse, MD
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT07569250 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 75 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07569250 currently recruiting?
Yes, NCT07569250 is actively recruiting participants. Contact the research team at yamila.sierra@cuanschutz.edu for enrollment information.
Where is the NCT07569250 trial being conducted?
This trial is being conducted at Boston, United States, Boston, United States, Boston, United States, Dallas, United States.
Who is sponsoring the NCT07569250 clinical trial?
NCT07569250 is sponsored by University of Colorado, Denver. The principal investigator is Gina Kruse, MD at University of Colorado, Denver. The trial plans to enroll 7,220 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.